ADIPOQ in NAFLD patients is a risk factor for progression to liver cancer, and ADIPOQ is significantly decreased in patients with liver metastases [73]. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.